Document Type: Original Article
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
Material and Nuclear Fuel Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
Introduction: The aim of this study was to evaluate the human organ absorbed dose of [111In]In-DTPA-antiMUC1, as a newly developed radioimmunoconjugate.
Methods: [111In]In-DTPA-antiMUC1 was prepared at optimized conditions while the radiochemical purity of the tracer was investigated using ITLC method. Biodistribution of the radiolabeled complex was assessed in tumor bearing BALB/c mice and the human absorbed dose of the radiotracer was estimated based on the gathered data in animals according to the standard methods.
Results: The highest absorbed dose is observed in the spleen and the liver with 0.112 and 0.087 mGy/MBq, respectively. In addition, the estimated human equivalent and effective absorbed dose were 0.008 mGy/MBq and 0.041 mSv/MBq, respectively.
Conclusion: [111In]In-DTPA-antiMUC1 radioimmunoconjugate can be considered as an effective and safe radiolabeled compound for MUC1 positive breast cancer SPECT imaging.